Sirolimus: A New Hope for Feline Hypertrophic Cardiomyopathy (HCM) Treatment
Sirolimus (rapamycin), also felycin-CA-1, is an FDA-approved drug for subclinical feline HCM, reducing heart muscle thickening. It targets mTORC1, with conditional approval from the RAPACAT trial and ongoing HALT study. Strict diagnostic criteria and monitoring are essential for its use.